A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

To join this study, participants generally need to have a confirmed diagnosis of prostate cancer that started in the glands and has evidence of spreading to other parts of the body. Their cancer must have progressed despite hormone treatment, and they should have already received at least one or two specific types of hormone-blocking medicines. They also need to be able to carry out their daily activities quite well, as measured by a doctor.

There are also some reasons why someone might not be able to join. For instance, if you have certain lung conditions, like a history of serious lung inflammation, or have uncontrolled heart disease or uncontrolled diabetes, you likely wouldn't be eligible. Men who have recently undergone certain chemotherapy treatments or radiotherapy might also be excluded for safety reasons.

It's important to remember that these are just some of the main points. A full assessment by the study doctors will be needed to determine if someone is a good fit for the trial, considering all aspects of their health.

If you are eligible and choose to take part in this study, you would receive the study treatment, which could be ifinatamab deruxtecan (I-DXd) alone or in combination with other established medicines. The frequency of your visits to the clinic would depend on the specific treatment plan, but typically involves regular check-ups, blood tests (including PSA levels), and other assessments to monitor your health and how the treatment is working. This helps the researchers understand the effects of the treatment and manage any side effects. You might also have scans to check your cancer. The total duration of participation in the study, including follow-up after treatment, would be discussed in detail by the study team.